Listed

Fate Therapeutics Inc: Form 10-Q for the period ended Mar 31, 2023

Filed with the SEC on May 3, 2023 and accepted by EDGAR at May 3, 2023, 16:10 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-01-01 to 2023-03-31$59.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2023-01-01 to 2023-03-31$65.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2023-01-01 to 2023-03-31−$28.6mus-gaap:OperatingIncomeLoss
Net income3 months2023-01-01 to 2023-03-31−$18.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-01-01 to 2023-03-31−$0.19us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-01-01 to 2023-03-31−$0.19us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-01-01 to 2023-03-3198,054,687 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2023-01-01 to 2023-03-31−$28.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-01-01 to 2023-03-31$3.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2023-03-31$42.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-03-31$437.9mus-gaap:AssetsCurrent
Total assetsAt period end2023-03-31$630.3mus-gaap:Assets
Current liabilitiesAt period end2023-03-31$48.7mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2023-03-31$477.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-23-017175. Last ingested by Listed: Nov 14, 2026, 10:50 ET. Listed shows no prices and gives no investment advice.